A proposed securities class action is pursuing claims against PROCEPT BioRobotics Corporation on behalf of investors who bought PRCT common stock between February 28, 2024 and February 25, 2026, alleging the company used an undisclosed discount program to pull forward bulk handpiece orders beyond procedure demand and inflate reported U.S. handpiece unit sales and revenue. The complaint says the mismatch between orders and underlying procedures widened through the class period, leaving more than 10,000 excess units in field inventory by the end of the period and undermining statements about sales, system utilization and 2025 guidance. The suit points to a series of earnings disclosures, including August and November 2025 updates showing weaker shipments and lower handpiece guidance, before a February 25, 2026 disclosure said sales had exceeded procedures in every quarter since early 2023 and the discount program was being ended. PROCEPT shares fell from $27.84 to $22.69 over the next two trading days, and investors have until September 22, 2026 to seek appointment as lead plaintiff.